Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Cutaneous photosensitivity and lethal colitisis is a rare inflammatory bowel disease characterized by early cutaneous photosensitivity manifesting by sun-induced facial erythematous and vesicular lesions and severe recurent colitis which lead to untreatable diarrhea. There have been no further descriptions in the literature since 1991.
Features include: Diarrhea, Colitis, Early cutaneous photosensitivity, and Erythema.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 2 | Diarrhea, Colitis |
Skin | 2 | Early cutaneous photosensitivity, Erythema |
Biomarker and diagnostic research for cutaneous photosensitivity-lethal colitis syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for cutaneous photosensitivity-lethal colitis syndrome.
19 publications have been identified in PubMed for cutaneous photosensitivity-lethal colitis syndrome. Research spans Case Report / Case Series (42%), Review / Meta-Analysis (26%), and Basic Science / Preclinical (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 42% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:51 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries
5 |
26% |
Laboratory research | 3 | 16% |
Testing and diagnosis research | 1 | 5% |
Clinical study results | 1 | 5% |
Disease patterns and progression | 1 | 5% |
Palmeri S (2026). [PMID: 41365842](https://pubmed.ncbi.nlm.nih.gov/41365842/). *Rheumatology (Oxford, England)*. [Case Report / Case Series]
Nitskovich R (2026). [PMID: 41722086](https://pubmed.ncbi.nlm.nih.gov/41722086/). *Archivum immunologiae et therapiae experimentalis*. [Review / Meta-Analysis]
El Tahech S (2026). [PMID: 41704985](https://pubmed.ncbi.nlm.nih.gov/41704985/). *Cureus*. [Case Report / Case Series]
Tsilimpotis D (2026). [PMID: 41136229](https://pubmed.ncbi.nlm.nih.gov/41136229/). *Inflammatory bowel diseases*. [Review / Meta-Analysis]
Babino G (2026). [PMID: 42146941](https://pubmed.ncbi.nlm.nih.gov/42146941/). *Case Rep Med*. [Diagnostic / Biomarker]
Barquero-Orias D (2026). [PMID: 42030133](https://pubmed.ncbi.nlm.nih.gov/42030133/). *Rev Gastroenterol Peru*. [Review / Meta-Analysis]
Malik TF (2026). [PMID: 33760556](https://pubmed.ncbi.nlm.nih.gov/33760556/). *Unknown Journal*. [Review / Meta-Analysis]
Giordano A (2025). [PMID: 41658563](https://pubmed.ncbi.nlm.nih.gov/41658563/). *Frontiers in oncology*. [Case Report / Case Series]
Lin TM (2025). [PMID: 40721277](https://pubmed.ncbi.nlm.nih.gov/40721277/). *Clinical and experimental dermatology*. [Epidemiology / Natural History]
Kwan KR (2024). [PMID: 38204187](https://pubmed.ncbi.nlm.nih.gov/38204187/). *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. [Basic Science / Preclinical]